Clinical trials
Phase 2 Inflammatory Breast Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 5 |
| 2007 | 4 |
| 2008 | 1 |
| 2010 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Active, not recruiting | 9 |
| Terminated | 8 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 11 |
| City of Hope Medical Center | 5 |
| National Cancer Institute (NCI) | 3 |
| Dana-Farber Cancer Institute | 2 |
| GlaxoSmithKline | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Academic and Community Cancer Research United | 1 |
| BerGenBio ASA | 1 |
| Filipa Lynce, MD | 1 |
| Fred Hutchinson Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammatory Breast Neoplasms | 41 |
| Breast Neoplasms | 34 |
| Triple Negative Breast Neoplasms | 8 |
| Breast Neoplasms, Male | 4 |
| Carcinoma, Ductal, Breast | 4 |
| Carcinoma, Lobular | 4 |
| Edema | 2 |
| Erythema | 2 |
| Disease | 1 |
| Unilateral Breast Neoplasms | 1 |
Trials
Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.